Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.


Salivary Gland-type Carcinoma of the Lung (SGTTL)

Salivary gland-type carcinoma of the lung (SGTTL) is a rare and challenging malignancy that affects the lungs. Our company is at the forefront of drug and therapy development services aimed at combating SGTTLs. We have a professional team to provide one-stop solutions for global pharmaceutical companies.

Overview of Salivary Gland-type Carcinoma of the Lung (SGTTL)

Salivary gland-type carcinoma of the lung (SGTTL), also known as lung carcinomas of the salivary gland type or bronchial gland neoplasms, is a rare type of lung cancer that originates from the salivary glands. SGTTLs represent 1% or less of all lung tumors. It is characterized by the presence of tumor cells with histological features resembling salivary gland tumors. Genetic alterations, such as gene fusions involving NTRK, are commonly observed in SGTTLs. Additionally, exposure to certain carcinogens, such as tobacco smoke and environmental pollutants, may contribute to the development of lung cancer, including SGTTLs.

Fig.1 Histopathologic features of salivary gland-type lung carcinoma.Fig.1 Histopathologic features of salivary gland-type lung carcinoma. (Wang, Minhua, et al., 2021)

Diagnostics of SGTTL

  • Histopathology and Immunohistochemistry
    Histopathological evaluation of lung biopsy or cytology specimens remains the gold standard for diagnosing SGTTLs. The presence of tumor cells with salivary gland-like features, such as ductal structures, clear cells, or mucinous components, can aid in the diagnosis. Immunohistochemistry is a valuable ancillary tool in confirming the diagnosis of SGTTLs. Markers such as CK7, p63, and S100 can help differentiate SGTTLs from other lung cancers.
  • Molecular Analysis
    Molecular analysis has revolutionized cancer diagnostics and plays a crucial role in identifying specific genetic alterations in SGTTLs. Gene fusions involving NTRK are commonly observed in SGTTLs and can serve as a diagnostic marker. Other molecular alterations, such as mutations in the TP53 gene or the presence of specific oncogenic drivers, can also help in the diagnosis and further characterization of SGTTLs.

In addition, several genetic rearrangements have been identified that may help diagnose these tumors, but have not yet been associated with molecularly targeted therapies.

  • Rearrangements of the EWSR1 locus or FUS (TLS) locus in myoepithelioma and myoepithelial carcinoma.
  • CRTC1::MAML2 rearrangements in mucoepidermoid carcinoma
  • MYB::NF1B rearrangements in adenoid cystic carcinoma
  • EWSR1::ATF1 rearrangements in hyalinizing clear cell carcinoma

Therapy Development for SGTTL

Targeted Therapy

NTRK gene fusion, which is common in SGTTLs, is an attractive therapeutic target. The development of targeted therapies that inhibit the abnormal NTRK signaling pathway aims to prevent the growth and progression of SGTTLs by blocking the oncogenic effects of NTRK fusion.


Immunotherapy has revolutionized cancer therapeutic strategies by harnessing the body's immune system to fight cancer cells. For example, among people with SGC who received pembrolizumab, the overall response rate (ORR) was 12%.Immunotherapy approaches have great potential in SGTTLs. By modulating the immune response, these therapies enhance the body's ability to recognize and eliminate cancer cells.

Our Services

Accurate diagnosis of SGTTLs is essential for appropriate therapy development planning. Diagnosing SGTTLs can be challenging due to their rarity and overlapping features with other lung tumors. However, advancements in diagnostic techniques have improved our ability to identify and differentiate SGTTLs from other lung malignancies. In addition to diagnostics development services, we have diverse therapy development solutions.

Therapy Development Platforms

Our company is committed to screening targeted therapies for SGTTLs by building animal models. Through comprehensive research and collaboration, we aim to provide a full suite of preclinical research services, including drug safety evaluation as well as pharmacokinetic analysis, to further accelerate the development of your SGTTL drugs and therapies.

Animal Models of SGTTL

  • Orthotopic nude mouse models
  • Others

If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Wang, Minhua, et al. "Salivary gland-type tumors of the lung: a distinct group of uncommon lung tumors." Archives of Pathology & Laboratory Medicine 145.11 (2021): 1379-1386.
  • Hu, Shumin, et al. "Pulmonary salivary gland tumor, mucoepidermoid carcinoma: A literature review." Journal of Oncology 2022 (2022).

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services

Copyright © Protheragen. All rights reserves.